Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 1.77%. A quarter ago, it was expected that this company would post a loss of $1.45 per share when it actually produced a loss of $1.21, delivering a surprise of 16.55%. Over the last four quarters, the company has ...